Tot Biopharm Completes $66.5 Million Hong Kong IPO

23:49 EST 7 Nov 2019 | ChinaBio Today

Suzhou's Tot Biopharm completed a $66.5 million IPO on the Hong Kong Exchange to support development of its novel and biosimilar cancer drugs. Tot's portfolio consists of seven biological and five chemical candidates, all but one of them developed in-house. Its products include mAbs, antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs. Tot's lead product is an Avastin biosimilar that is expected to launch in late 2020 or early 2021. More details....

Stock Symbol: (HK: 1875)

Share this with colleagues:

Original Article: Tot Biopharm Completes $66.5 Million Hong Kong IPO


More From BioPortfolio on "Tot Biopharm Completes $66.5 Million Hong Kong IPO"

Quick Search

Relevant Topics

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...